Drug Trial Radar · NCT07935317
A Study of Tersolisib (LY4064809) and Abemaciclib With Hormone Therapies in Participants With PIK3CA-Mutated Early Breast Cancer
Last checked: Nov 19, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
120
Planned (sponsor's estimate)
Start
Dec 2026
Primary completion
Dec 2027
Study completion Jan 2028
Sponsor
- Lead sponsor
- Eli Lilly and CompanyEli Lilly (LLY)
- Sponsor type
- Industry
- First posted
- Nov 13, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main purpose of this study is to compare two ways of giving the anti-cancer medicines abemaciclib and hormone therapy with tersolisib in participants with early breast cancer that has a genetic mutation (PIK3CA mutation). For each participant, the study will last up to 56 weeks and include 12 visits.
Conditions
- Breast Neoplasms
Interventions
AbemaciclibDrug
Administered orally
TersolisibDrug
Administered orally
LetrozoleDrug
Administered orally
AnastrozoleDrug
Administered orally
ExemestaneDrug
Administered orally
Primary outcomes
What the sponsor says the trial is designed to measure.
- Rate of Participants who Discontinue Tersolisib Due to Treatment Emergent Adverse Events (TEAEs).Time frame: Cycle 1 through study completion (estimated as 56 weeks)
Locations
9 sites in 1 country. Site status is shown where the registry gives one.
Cancer and Blood Specialty Clinic
Los Alamitos, California
USO - Rocky Mountain Cancer Centers
Lakewood, Colorado
Winship Cancer Institute, Emory University
Atlanta, Georgia
Dana-Farber Cancer Institute
Boston, Massachusetts
Stefanie Spielman Comprehensive Breast Center
Columbus, Ohio
Texas Oncology - West Texas
Amarillo, Texas
Texas Oncology - Balcones
Austin, Texas
South Texas Accelerated Research Therapeutics (START)
San Antonio, Texas
USO - Virginia Cancer Specialists
Reston, Virginia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.